Reading view
Recapitulating lung cancer metastasis in vitro: Advances in organoid models and challenges in clinical translation (Review)
Oncol Rep. 2026 Mar;55(3):49. doi: 10.3892/or.2026.9054. Epub 2026 Jan 23.
ABSTRACT
Lung cancer remains a significant global health challenge, with metastatic progression being the leading driver of mortality. Organoid technology provides a tractable, physiologically relevant platform to model key aspects of lung cancer metastasis in vitro. The present review summarized methodologies for constructing and interrogating these models, covering tissue sources, culture modalities, gene editing and in vivo transplantation; applications in studying metastatic mechanisms, drug screening and capturing intra‑ and intertumoral heterogeneity are also highlighted. Persistent challenges include standardizing derivation and culture conditions, improving preservation of tumor‑microenvironmental interactions, expanding immune‑competent and vascularized models, and addressing scalability, cost, and regulatory and ethical considerations for clinical translation. Future directions include integrating multi‑omics approaches and spatial profiling, leveraging artificial intelligence for image and response analytics, advancing immune‑organoid models and establishing shared standards, reference materials and reporting guidelines to enhance reproducibility and clinical impact.
PMID:41574717 | DOI:10.3892/or.2026.9054
Former CEO of celeb fav gym Dogpound launches $5M fund to back wellness companies
The Responsibility Vacuum: Organizational Failure in Scaled Agent Systems
An Optimized Decision Tree-Based Framework for Explainable IoT Anomaly Detection
Towards Execution-Grounded Automated AI Research
Automated Rubrics for Reliable Evaluation of Medical Dialogue Systems
Manalyzer: End-to-end Automated Meta-analysis with Multi-agent System
Large language models improve transferability of electronic health record-based predictions across countries and coding systems
npj Digital Medicine, Published online: 22 January 2026; doi:10.1038/s41746-026-02363-5
Large language models improve transferability of electronic health record-based predictions across countries and coding systemsMultimodal AI generates virtual population for tumor microenvironment modeling
STAT+: OpenEvidence raises $250 million, doubling its valuation
OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding.
The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians.
Founded in 2022, OpenEvidence is one of the most prominent and best-funded companies from a wave of health artificial intelligence companies that emerged since the widespread availability of large language models. Reflecting on the eye-popping fundraising for health AI, a Silicon Valley Bank report released earlier in January raised an eyebrow at the ability of companies like OpenEvidence to deliver on their stratospheric valuations with advertising and software-as-a-service business models. “It won’t be a surprise to see them tap the value of the data they’re already collecting” to offer more services to pharma or other customers, the authors wrote.
Continue to STAT+ to read the full story…


© Adobe